Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum

Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum




Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum

LifeSci Genetics Medicine Conference on June 22, 2021 at 10:00 am ET

LSX Biotech Growth CEO Forum on June 22, 2021 at 1:10 pm ET

DALLAS–(BUSINESS WIRE)–Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.

Conferences Details:

Event:

 

LifeSci Genetics Medicine Conference

Date:

 

Tuesday, June 22, 2021

Time:

 

10:00 am ET

Format:

 

Fireside chat

Participants:

 

RA Session II, President, Founder and CEO

 

Dr. Suyash Prasad, Chief Medical Officer and Head of R&D

 

Kamran Alam, Chief Financial Officer

 

 

Event:

 

LSX Biotech Growth CEO Forum

Topic:

 

“Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering”

Date:

 

Tuesday, June 22, 2021

Time:

 

1:10 pm ET

Format:

 

Fireside chat

Participants:

 

RA Session II, President, Founder and CEO

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Contacts

Company Contact:
Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:
Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com